Compare Lockheed Martin Corporation (LMT) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Nuwellis Inc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Lockheed Martin Corporation is far larger — about 53281.8× Nuwellis Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Nuwellis Inc for 26 Days on average.
| LMT | NUWE | |
|---|---|---|
Market Cap | $117.22B | $2.20M |
Volume | 1,101,121 | 121,544 |
Sector | Industrials | Health |
52-Week High | $676.70 | $146.65 |
52-Week Low | $439.19 | $0.68 |
Typical Hold Time | 86 Days | 26 Days |
Enterprise Value | $133.96B | -$1.52M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed in Q4 2025 and Q1 2026, with revenue growth from $71B in 2024 to $75B in 2025. Analyst consensus is strongly bullish with 59% buy ratings and a $635.33 price target, representing 25% upside. Recent news highlights dividend increases for 23 straight years and strategic AI partnerships through Skunk Works innovation.
LMT offers attractive valuation with P/E of 18.73 and strong defense contract backlog, though recent earnings misses and rising debt-to-asset ratio to 36.44% pose execution risks. The stock presents value opportunity amid sustained Pentagon spending, but investors should monitor contract performance and interest rate sensitivity given $19.63B long-term debt.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
